Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 5/2006

01.08.2006 | Original Article

The effect of hormone replacement therapy on the levels of serum lipids, apolipoprotein AI, apolipoprotein B and lipoprotein (a) in Turkish postmenopausal women

verfasst von: Ahmet Bayrak, Derya (Akaydın) Aldemir, Tülin Bayrak, Aydın Çorakçı, Polat Dursun

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 5/2006

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Estrogen replacement therapy alters the lipid profiles favorably for delaying atherosclerosis in postmenopausal women. The effects of estrogen plus progesterone combination therapy on lipids are controversial. This study was designed to evaluate the effect of female sex hormones on lipids and lipoproteins and to clarify the influence of progesterone on the effect of estrogen in postmenopausal women.

Methods

Of the 60 postmenopausal women admitted to our menopause clinic, 40 had intact uterus and received continuous 0.625 mg conjugated equine estrogen (CEE) plus 2.5 mg medroxyprogesterone acetate (MPA), whereas the remaining 20 were hysterectomized and received 0.625 mg CEE daily. To assess the alterations in lipids and lipoproteins during menopause, 45 healthy premenopausal women were investigated. Lipid and lipoprotein levels were assessed in each subject at baseline and at the 6th and 18th months of therapy.

Results

In menopause, a shift towards more atherogenic lipid and lipoprotein profiles than those of the premenopausal state was found. Following 18 months of treatment, both regimens reduced total cholesterol (TC) levels as compared with the baseline (6.4 vs. 6.9% in the CEE/MPA and CEE groups, respectively). The CEE group had a more pronounced increase in high-density lipoprotein (HDL) cholesterol than the CEE/MPA group (10.3 vs. 8.8%, respectively). Both groups displayed reduced TC, low-density lipoprotein (LDL) cholesterol and apolipoprotein-B (ApoB) concentrations, whereas triglycerides increased, with a greater tendency to increase in the CEE/MPA group at the end of the trial. Also, the lipoprotein (a) [Lp(a)] levels decreased significantly (27.6 vs. 24.5% in the CEE/MPA and CEE groups, respectively). This decrease was more pronounced in subjects with a relatively higher basal Lp(a) concentration.

Conclusion

Both treatment regimens caused positive alterations in the lipid and lipoprotein profiles. This association might play a pivotal role in the postmenopausal increases in atherosclerotic diseases and cardioprotective effect of estrogen in postmenopausal women.
Literatur
1.
Zurück zum Zitat Nathan L, Chaudhuri G (1997) Estrogens and atherosclerosis. Annu Rev Pharmacol Toxicol l37:477–515CrossRef Nathan L, Chaudhuri G (1997) Estrogens and atherosclerosis. Annu Rev Pharmacol Toxicol l37:477–515CrossRef
2.
Zurück zum Zitat Chang TC, Lien YR, Chen M, Cheng SP et al (2004) Effect of conjugated eguine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study. Acta Obstet Gynecol Scand 83:661–666PubMedCrossRef Chang TC, Lien YR, Chen M, Cheng SP et al (2004) Effect of conjugated eguine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study. Acta Obstet Gynecol Scand 83:661–666PubMedCrossRef
3.
Zurück zum Zitat Christodoulakos GE, Lambrinoudaki IV, Panoulis CP, Papadias CA, Kouskouni EE et al (2004) Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids and lipoprotein in Greek postmenopausal women. Gynecol Endocrinol 18:244–257PubMedCrossRef Christodoulakos GE, Lambrinoudaki IV, Panoulis CP, Papadias CA, Kouskouni EE et al (2004) Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids and lipoprotein in Greek postmenopausal women. Gynecol Endocrinol 18:244–257PubMedCrossRef
4.
Zurück zum Zitat Solomon CG, Dluhy (2003) Rethinking postmenopausal hormone therapy. N Engl J Med 348:579–580PubMedCrossRef Solomon CG, Dluhy (2003) Rethinking postmenopausal hormone therapy. N Engl J Med 348:579–580PubMedCrossRef
5.
Zurück zum Zitat Writing Group for the Women’s Health Initiative (WHI) Investigators (2002) Risk and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288:321–333CrossRef Writing Group for the Women’s Health Initiative (WHI) Investigators (2002) Risk and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288:321–333CrossRef
6.
Zurück zum Zitat Grady D, Yaffe K, Kristof M, Lin F, Richards C, Barrett-Connor E (2002) Effect of postmenopausal hormone therapy on cognatitive function: The Heart and Estrogen/Progestin Replacement Study. Am J Med 113:543–548PubMedCrossRef Grady D, Yaffe K, Kristof M, Lin F, Richards C, Barrett-Connor E (2002) Effect of postmenopausal hormone therapy on cognatitive function: The Heart and Estrogen/Progestin Replacement Study. Am J Med 113:543–548PubMedCrossRef
7.
Zurück zum Zitat Ettinger B, Friedman GD, Bush T, Quesenberry CP (1996) Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 87:6–12PubMedCrossRef Ettinger B, Friedman GD, Bush T, Quesenberry CP (1996) Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 87:6–12PubMedCrossRef
8.
Zurück zum Zitat Wiklund I, Karlberg J, Mattsson LA (1993) Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am J Obstet Gynecol 168:824–830PubMed Wiklund I, Karlberg J, Mattsson LA (1993) Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am J Obstet Gynecol 168:824–830PubMed
9.
Zurück zum Zitat Grady D (2003) Postmenopausal hormones—therapy for symptoms only. N Engl J Med 348:1835–1837PubMedCrossRef Grady D (2003) Postmenopausal hormones—therapy for symptoms only. N Engl J Med 348:1835–1837PubMedCrossRef
10.
Zurück zum Zitat Grambrell RD Jr (1982) The menopause: benefits and risk of estrogen-progestogen replacement therapy. Fertil Steril 37:457–474 Grambrell RD Jr (1982) The menopause: benefits and risk of estrogen-progestogen replacement therapy. Fertil Steril 37:457–474
11.
Zurück zum Zitat Wolf PH, Madans JH, Finucane FF, Higgins M, Kleinman JC (1991) Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol 164:489–494PubMed Wolf PH, Madans JH, Finucane FF, Higgins M, Kleinman JC (1991) Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol 164:489–494PubMed
12.
Zurück zum Zitat Gibbons WF, Judd HL, Luciano AA et al (1991) Comparison sequential versus continious estrogen/progestin replacement therapy on serum lipid patterns: Multiuniversity National Upjohn study Collaborative. Society for Gynecologic Investigation Gibbons WF, Judd HL, Luciano AA et al (1991) Comparison sequential versus continious estrogen/progestin replacement therapy on serum lipid patterns: Multiuniversity National Upjohn study Collaborative. Society for Gynecologic Investigation
13.
Zurück zum Zitat Odmark IS, Backstrom T, Haeger M, Jonsson B, Bixo M (2004) Effects of continous combined conjugated estrogen/medroxyprogesterone acetate on lipids and lipoproteins. Maturitas 48:137–146PubMedCrossRef Odmark IS, Backstrom T, Haeger M, Jonsson B, Bixo M (2004) Effects of continous combined conjugated estrogen/medroxyprogesterone acetate on lipids and lipoproteins. Maturitas 48:137–146PubMedCrossRef
14.
Zurück zum Zitat Hirvonen E, Malkonen M, Mannihen V (1981) Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med 304:560–563PubMedCrossRef Hirvonen E, Malkonen M, Mannihen V (1981) Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med 304:560–563PubMedCrossRef
15.
Zurück zum Zitat Lobo RA, Pickar JH, Wild RA, Wash B et al (1994) Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 84:987–995PubMed Lobo RA, Pickar JH, Wild RA, Wash B et al (1994) Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 84:987–995PubMed
16.
Zurück zum Zitat Kim CJ, Jang HC, Cho DH, Min YK (1994) Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women. Arterioscler Thromb Vasc Biol 14:275–281 Kim CJ, Jang HC, Cho DH, Min YK (1994) Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women. Arterioscler Thromb Vasc Biol 14:275–281
17.
Zurück zum Zitat Gurakar A, Hoeg JM, Kostner G, Papadopoulos NM et al (1985) Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis 57:293–301PubMedCrossRef Gurakar A, Hoeg JM, Kostner G, Papadopoulos NM et al (1985) Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis 57:293–301PubMedCrossRef
18.
Zurück zum Zitat Meilahn EN, Kuller LH, Matthews KA, Stein EA (1991) Lp(a) concentrations among pre-and postmenopausal women over time: the Healthy Women Study. Circulation 84(suppl II):II-546. Abstract Meilahn EN, Kuller LH, Matthews KA, Stein EA (1991) Lp(a) concentrations among pre-and postmenopausal women over time: the Healthy Women Study. Circulation 84(suppl II):II-546. Abstract
19.
Zurück zum Zitat Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G et al (1993) Association of hormone-replacement theraby with various cardiovascular risk factors in postmenopausal women. N Engl J Med 15:1069–1075CrossRef Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G et al (1993) Association of hormone-replacement theraby with various cardiovascular risk factors in postmenopausal women. N Engl J Med 15:1069–1075CrossRef
20.
Zurück zum Zitat Wahl P, Walden CW, Knopp R, Hoover J et al (1983) Effect of estrogen progestin potency on lipid/lipoprotein cholesterol. N Engl J Med 308:862–867PubMedCrossRef Wahl P, Walden CW, Knopp R, Hoover J et al (1983) Effect of estrogen progestin potency on lipid/lipoprotein cholesterol. N Engl J Med 308:862–867PubMedCrossRef
21.
Zurück zum Zitat Hirvonen E, Maelkoenen M, Manninen V (1981) Effect of different progestogen on lipoproteins during postmenopausal replacement therapy. N Engl J Med 304:560–563PubMedCrossRef Hirvonen E, Maelkoenen M, Manninen V (1981) Effect of different progestogen on lipoproteins during postmenopausal replacement therapy. N Engl J Med 304:560–563PubMedCrossRef
22.
Zurück zum Zitat Kannel WB, Hjoortland MC, McNamara PM, Gordon T (1976) Menopause and risk of cardiovascular disease. The Framingham Study. Ann Intern Med 85:447–452PubMed Kannel WB, Hjoortland MC, McNamara PM, Gordon T (1976) Menopause and risk of cardiovascular disease. The Framingham Study. Ann Intern Med 85:447–452PubMed
23.
Zurück zum Zitat Smith DC, Prentice R, Thompson DJ, Herrman WL (1975) Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 293:1164–1167PubMedCrossRef Smith DC, Prentice R, Thompson DJ, Herrman WL (1975) Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 293:1164–1167PubMedCrossRef
24.
Zurück zum Zitat Aygen EM, Basbug M, Tayyar M, Kaya E (1988) The effects of different doses of medroxyprogesterone acetate on serum lipids, lipoprotein levels and atherogenic index in the menopausal period. Gynecol Endocrinol 12:267–272CrossRef Aygen EM, Basbug M, Tayyar M, Kaya E (1988) The effects of different doses of medroxyprogesterone acetate on serum lipids, lipoprotein levels and atherogenic index in the menopausal period. Gynecol Endocrinol 12:267–272CrossRef
25.
Zurück zum Zitat Green A, Brain C (1993) Epidemiological overview of estrogen replacement and cardiovascular disease. Balliere’s Clin Endocrinol Metab 7:95–112CrossRef Green A, Brain C (1993) Epidemiological overview of estrogen replacement and cardiovascular disease. Balliere’s Clin Endocrinol Metab 7:95–112CrossRef
26.
Zurück zum Zitat Ylikorkala O, Lim P, Caubel P (2000) Effects on serum lipid profiles of continuous combined 17B-estradiol/norethisterone acetate hormone replacement therapy. Clin Ther 22:622–626PubMedCrossRef Ylikorkala O, Lim P, Caubel P (2000) Effects on serum lipid profiles of continuous combined 17B-estradiol/norethisterone acetate hormone replacement therapy. Clin Ther 22:622–626PubMedCrossRef
27.
Zurück zum Zitat Kojima K, Abe-Dohmae S, Arakawa R et al (2001) Progesterone inhibits apolipoprotein-mediated cellular lipid release: a putative mechanism for the decrease of high-density lipoprotein. Biochim Biophys Acta 1532:173–184PubMed Kojima K, Abe-Dohmae S, Arakawa R et al (2001) Progesterone inhibits apolipoprotein-mediated cellular lipid release: a putative mechanism for the decrease of high-density lipoprotein. Biochim Biophys Acta 1532:173–184PubMed
28.
Zurück zum Zitat Godsland IF (2001) Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein and apolipoprotein(a) concentrations: analysis of studies published from 1974–2000. Fertil Steril 75:898–915PubMedCrossRef Godsland IF (2001) Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein and apolipoprotein(a) concentrations: analysis of studies published from 1974–2000. Fertil Steril 75:898–915PubMedCrossRef
29.
Zurück zum Zitat van Baal WM, Kenemans P, Emeis JJ et al (1999) Long-term effects of combined hormone replacement therapy on markers of endothelial functial and inflammatory activity in healthy postmenopausal women. Fertil Steril 71:663–670PubMedCrossRef van Baal WM, Kenemans P, Emeis JJ et al (1999) Long-term effects of combined hormone replacement therapy on markers of endothelial functial and inflammatory activity in healthy postmenopausal women. Fertil Steril 71:663–670PubMedCrossRef
30.
Zurück zum Zitat Knopp RH (1998) The effect of postmenopausal estrogen therapy on the incidence of arteriosclerotic vascular disease. Obstet Gynecol 72:23S–30S Knopp RH (1998) The effect of postmenopausal estrogen therapy on the incidence of arteriosclerotic vascular disease. Obstet Gynecol 72:23S–30S
31.
Zurück zum Zitat Baracat EC, Barbosa IC, Giordano MG et al (2002) A randomised, open-lable study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects of symptom control, bleeding pattern, lipid profile and tolerability. Climacteric 5:60–69PubMedCrossRef Baracat EC, Barbosa IC, Giordano MG et al (2002) A randomised, open-lable study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects of symptom control, bleeding pattern, lipid profile and tolerability. Climacteric 5:60–69PubMedCrossRef
32.
Zurück zum Zitat Mendelsohn ME, Karas RH (1999) The protective effects of estrogen on the cardiovascular system. N Engl J med 340:1801–1811PubMedCrossRef Mendelsohn ME, Karas RH (1999) The protective effects of estrogen on the cardiovascular system. N Engl J med 340:1801–1811PubMedCrossRef
33.
Zurück zum Zitat Erenus M, Karakoc B, Gurler A (2001) Comprasion of effects of continuous combined transdermal with oral estrogen and oral progestogen replacement therapies on serum lipoproteins and compliance. Climacteric 4:228–234PubMedCrossRef Erenus M, Karakoc B, Gurler A (2001) Comprasion of effects of continuous combined transdermal with oral estrogen and oral progestogen replacement therapies on serum lipoproteins and compliance. Climacteric 4:228–234PubMedCrossRef
34.
Zurück zum Zitat Paterson ME, Sturdee DW, Moore B, Whitehead TP (1980) The effect of various regimens of hormone therapy on serum cholesterol and triglyceride concentrations in postmenopausal women. Br J Obstet Gynecol 87:552–560 Paterson ME, Sturdee DW, Moore B, Whitehead TP (1980) The effect of various regimens of hormone therapy on serum cholesterol and triglyceride concentrations in postmenopausal women. Br J Obstet Gynecol 87:552–560
35.
Zurück zum Zitat Barrett-Connor E, Wingard DL, Criqui MH (1989) Postmenopausal estrogen use and heart disease risk factors in the 1980s. Rancho Bernardo, Calif, revisited. J Am Med Assoc 261:2095–2100CrossRef Barrett-Connor E, Wingard DL, Criqui MH (1989) Postmenopausal estrogen use and heart disease risk factors in the 1980s. Rancho Bernardo, Calif, revisited. J Am Med Assoc 261:2095–2100CrossRef
36.
Zurück zum Zitat Notelovitz M, Gudat JC, Ware MD, Dougherty MC (1982) Estrogen-progestin therapy and the lipid balance of postmenopausal women. Maturitas 4:301–308PubMedCrossRef Notelovitz M, Gudat JC, Ware MD, Dougherty MC (1982) Estrogen-progestin therapy and the lipid balance of postmenopausal women. Maturitas 4:301–308PubMedCrossRef
37.
Zurück zum Zitat Campos H, Walsh BW, Judge H, Sacks FM (1997) Effect of estrogen on very low-density lipoprotein and low-density lipoprotein subclass metabolism in postmenopausal women. J Clin Endocrinol Metab 82:3955–3963PubMedCrossRef Campos H, Walsh BW, Judge H, Sacks FM (1997) Effect of estrogen on very low-density lipoprotein and low-density lipoprotein subclass metabolism in postmenopausal women. J Clin Endocrinol Metab 82:3955–3963PubMedCrossRef
38.
Zurück zum Zitat Hulley SB, Rosenman RH, Bawol RD, Brand RJ (1980) Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. N Engl J Med 302:1383–1389PubMedCrossRef Hulley SB, Rosenman RH, Bawol RD, Brand RJ (1980) Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. N Engl J Med 302:1383–1389PubMedCrossRef
39.
Zurück zum Zitat Chen FP, Lee N, Wang CC et al (1998) Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women. Fertil Steril 69:267–273PubMedCrossRef Chen FP, Lee N, Wang CC et al (1998) Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women. Fertil Steril 69:267–273PubMedCrossRef
40.
Zurück zum Zitat Walsh BW, Schiff I, Rosner B et al (1991) Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 325:1196–1204PubMedCrossRef Walsh BW, Schiff I, Rosner B et al (1991) Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 325:1196–1204PubMedCrossRef
41.
Zurück zum Zitat Assmann G, Schulte H (1992) Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 70(7):733–737PubMedCrossRef Assmann G, Schulte H (1992) Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 70(7):733–737PubMedCrossRef
42.
Zurück zum Zitat Chen FP, Lee N, Soon YK et al (2001) Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on cargiovascular risk factors. Menopause 8:347–352PubMedCrossRef Chen FP, Lee N, Soon YK et al (2001) Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on cargiovascular risk factors. Menopause 8:347–352PubMedCrossRef
43.
Zurück zum Zitat Torng PL, Su TC, Sung FC, Chien KL, Huang SC, Chow SN et al (2000) Effects of menopause and obesity on lipid profiles in middle-aged Taiwanese women: the Chin-Shan Community Cardiovascular Cohort Study. Atherosclerosis 153:413–421PubMedCrossRef Torng PL, Su TC, Sung FC, Chien KL, Huang SC, Chow SN et al (2000) Effects of menopause and obesity on lipid profiles in middle-aged Taiwanese women: the Chin-Shan Community Cardiovascular Cohort Study. Atherosclerosis 153:413–421PubMedCrossRef
44.
Zurück zum Zitat Farish E, Fletcher CD, Hart DM, Dagen MM, Parkin DE (1986) Lipoprotein and apoprotein levels in postmenopausal women during treatment with norethisterone. Clin Chim Acta 159:147–151PubMedCrossRef Farish E, Fletcher CD, Hart DM, Dagen MM, Parkin DE (1986) Lipoprotein and apoprotein levels in postmenopausal women during treatment with norethisterone. Clin Chim Acta 159:147–151PubMedCrossRef
45.
Zurück zum Zitat Melchior GW, Castle CK, Vidmar TJ, Politers HG et al (1990) Apo A-I metabolism in cynomolgus monkeys: male-female differences. Biochem Biophys Acta 1043:97–105PubMed Melchior GW, Castle CK, Vidmar TJ, Politers HG et al (1990) Apo A-I metabolism in cynomolgus monkeys: male-female differences. Biochem Biophys Acta 1043:97–105PubMed
46.
Zurück zum Zitat Schaefer EJ, Foster DM, Zech LA, Lindgren FT et al (1983) The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab 57:262–267PubMedCrossRef Schaefer EJ, Foster DM, Zech LA, Lindgren FT et al (1983) The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab 57:262–267PubMedCrossRef
47.
Zurück zum Zitat Castelo-Branco C, Vicente JJ, Figueras F et al (1999) Two years prospective and comparative study on the effects of tibolone on lipid pattern, behavior of apolipoproteins AI and B. Menopause 6:22–27CrossRef Castelo-Branco C, Vicente JJ, Figueras F et al (1999) Two years prospective and comparative study on the effects of tibolone on lipid pattern, behavior of apolipoproteins AI and B. Menopause 6:22–27CrossRef
48.
Zurück zum Zitat Tonstad S (1996) Combined hormone replacement therapy vith estradiol and norethisterone acetate: effects in hyperlipidemia. Br J Obstet Gynecol 103(suppl 13):45–48 Tonstad S (1996) Combined hormone replacement therapy vith estradiol and norethisterone acetate: effects in hyperlipidemia. Br J Obstet Gynecol 103(suppl 13):45–48
49.
Zurück zum Zitat Soma M, Fumagalli R, Paoletti R et al (1991) Plasma Lp(a) concentration after estrogen and progestagen in postmenopausal women. Lancet 1:612CrossRef Soma M, Fumagalli R, Paoletti R et al (1991) Plasma Lp(a) concentration after estrogen and progestagen in postmenopausal women. Lancet 1:612CrossRef
50.
Zurück zum Zitat Brown SA, Hutchinson R, Morriseft J, Boerwinkle E, Davis CE, Gotto AM (1993) Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communites: The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 13:1139–1158 Brown SA, Hutchinson R, Morriseft J, Boerwinkle E, Davis CE, Gotto AM (1993) Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communites: The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 13:1139–1158
51.
Zurück zum Zitat Marcovina SM, Alber JJ, Jacobs DR Jr et al (1993) Lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in Caucasians and African Americans: The CARDIA Study. Arterioscler Thromb Vasc Biol 13:1037–1045 Marcovina SM, Alber JJ, Jacobs DR Jr et al (1993) Lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in Caucasians and African Americans: The CARDIA Study. Arterioscler Thromb Vasc Biol 13:1037–1045
52.
Zurück zum Zitat Jenner JL, Ordovas JM, Lamon-Fava S, Schaefer MM, Wilson PWF et al (1993) Effect of age, sex, and menopausal status on plasma lipoprotein(a) levels: the Framingham Offspring Study. Circulation 87:1135–1141PubMed Jenner JL, Ordovas JM, Lamon-Fava S, Schaefer MM, Wilson PWF et al (1993) Effect of age, sex, and menopausal status on plasma lipoprotein(a) levels: the Framingham Offspring Study. Circulation 87:1135–1141PubMed
53.
Zurück zum Zitat Smolders RG, Vogelvang TE, Mijatovic V et al (2002) A 2-year randomized, comparative study on the effects of reloxifene on lipoprotein(a) and homocysteine. Maturitas 4:105–114CrossRef Smolders RG, Vogelvang TE, Mijatovic V et al (2002) A 2-year randomized, comparative study on the effects of reloxifene on lipoprotein(a) and homocysteine. Maturitas 4:105–114CrossRef
54.
Zurück zum Zitat Bostom AG, Cupples LA, Jenner JL et al (1996) Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. J Am Med Assoc 276:544–548CrossRef Bostom AG, Cupples LA, Jenner JL et al (1996) Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. J Am Med Assoc 276:544–548CrossRef
55.
Zurück zum Zitat Kim CJ, Min YK, Ryu WS et al (1996) Effects of hormon replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of theray. Arch Intern Med 156:1693–1700PubMedCrossRef Kim CJ, Min YK, Ryu WS et al (1996) Effects of hormon replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of theray. Arch Intern Med 156:1693–1700PubMedCrossRef
56.
Zurück zum Zitat Schaefer EJ, Lamon-Fava S, Jenner JL et al (1994) Lipoprotein(a) levels and the risk of coronary heart disease in men: The Lipid research Clinics Coronary Primary Prevention Trial. JAMA 271:999–1003PubMedCrossRef Schaefer EJ, Lamon-Fava S, Jenner JL et al (1994) Lipoprotein(a) levels and the risk of coronary heart disease in men: The Lipid research Clinics Coronary Primary Prevention Trial. JAMA 271:999–1003PubMedCrossRef
57.
Zurück zum Zitat Walsh BW, Kuller LH, Wild RA et al (1998) Effects of raloxifene on serum lipids and coagulation factors in health postmenopausal women. J Am Med Assoc 279:1445–1451CrossRef Walsh BW, Kuller LH, Wild RA et al (1998) Effects of raloxifene on serum lipids and coagulation factors in health postmenopausal women. J Am Med Assoc 279:1445–1451CrossRef
Metadaten
Titel
The effect of hormone replacement therapy on the levels of serum lipids, apolipoprotein AI, apolipoprotein B and lipoprotein (a) in Turkish postmenopausal women
verfasst von
Ahmet Bayrak
Derya (Akaydın) Aldemir
Tülin Bayrak
Aydın Çorakçı
Polat Dursun
Publikationsdatum
01.08.2006
Verlag
Springer-Verlag
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 5/2006
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-006-0187-2

Weitere Artikel der Ausgabe 5/2006

Archives of Gynecology and Obstetrics 5/2006 Zur Ausgabe

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Menopausale Hormontherapie für Frauen über 65?

07.05.2024 Klimakterium und Menopause Nachrichten

In den USA erhalten nicht wenige Frauen auch noch im Alter über 65 eine menopausale Hormontherapie. Welche positiven und negativen gesundheitlichen Konsequenzen daraus möglicherweise resultieren, wurde anhand von Versicherungsdaten analysiert.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.